Zoledronic Acid [For hypercalcemia]: Brands, Price & Uses in Bangladesh

Approved Indication

Zoledronic Acid [For hypercalcemia] is indicated for the treatment of hypercalcemia of malignancy (HCM), defined as an albumin-corrected serum calcium level of ≥12 mg/dL (3 mmol/L). It is used to rapidly lower dangerously elevated calcium levels caused by certain cancers (e.g. squamous cell carcinomas, breast cancer, multiple myeloma, and other tumors producing humoral or local osteolytic hypercalcemia).

Other Zoledronic Acid Uses (Different Dose/Schedule – Not This Indication)

Zoledronic acid, as a molecule, is also used at different doses and dosing schedules for osteoporosis prevention/treatment, Paget's disease of bone, and to reduce skeletal-related events in bone metastases from solid tumors or multiple myeloma. These are separate regimens and are not the hypercalcemia-of-malignancy indication covered by Zoledronic Acid [For hypercalcemia]; do not substitute one dosing schedule for another.

Pre-treatment Requirements

• Patients must be adequately rehydrated with intravenous normal saline before and during administration of Zoledronic Acid [For hypercalcemia]; adequate urine output should be maintained, but forced diuresis should be avoided.
• Serum creatinine, calcium, phosphate, and magnesium should be assessed before administration.
• Pre-existing hypocalcemia and other electrolyte disturbances must be corrected before starting Zoledronic Acid [For hypercalcemia] (except the elevated calcium itself, which is the condition being treated).

Adult Dose for Hypercalcemia of Malignancy

Renal Function Monitoring

No dose adjustment of Zoledronic Acid [For hypercalcemia] is generally required for mild-to-moderate renal impairment when treating hypercalcemia of malignancy. In patients with severe renal impairment, the decision to use Zoledronic Acid [For hypercalcemia] should be individualized, weighing the risk of further renal deterioration against the risk of leaving life-threatening hypercalcemia untreated. Serum creatinine should be checked prior to each dose.

Pediatric Dose

Zoledronic Acid [For hypercalcemia] is not indicated for use in pediatric patients; safety and efficacy have not been established (see Pediatric Use).

Very Common / Common

• Acute phase reaction: fever, flu-like symptoms, myalgia, arthralgia, and bone pain, typically occurring within 1–3 days of the first infusion of Zoledronic Acid [For hypercalcemia] and resolving within a few days.
• Nausea, vomiting, constipation, loss of appetite
• Fatigue, weakness, headache
• Anemia
• Hypophosphatemia, hypocalcemia, hypomagnesemia
• Increase in serum creatinine (renal function changes)

Less Common but Serious

• Osteonecrosis of the jaw (ONJ) — see Precautions and Warnings.
• Atypical femur fractures (more associated with long-term/chronic bisphosphonate use) — see Precautions and Warnings.
• Acute renal failure, especially with pre-existing renal impairment, dehydration, or rapid infusion.
• Severe symptomatic hypocalcemia (muscle cramps, tetany, cardiac arrhythmia in severe cases).
• Ocular inflammation (uveitis, scleritis, conjunctivitis) — rare.
• Infusion-site reactions (redness, swelling, pain).